Search Result

Results for "

Allen proteasome Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Proteasome (83) ADC Antibody (2) Akt (4) Androgen Receptor (2) Apoptosis (34) Autophagy (14) Bacterial (6) Bcl-2 Family (1) BCL6 (1) Bcr-Abl (1) Biochemical Assay Reagents (1) c-Met/HGFR (1) c-Myc (1) Calcium Channel (1) CaMK (1) Caspase (1) CD38 (2) CDK (3) ClpP (1) Deubiquitinase (6) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (4) Endogenous Metabolite (3) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (1) Ferroptosis (3) FLT3 (1) Fungal (2) Glutaminase (1) Glutathione Peroxidase (1) HDAC (3) Hexokinase (1) Histone Methyltransferase (6) HIV (4) HSP (3) IGF-1R (1) IKK (1) IRAK (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Ligands for E3 Ligase (5) MAP4K (2) MDM-2/p53 (1) Mitophagy (1) MMP (1) Molecular Glues (1) NAMPT (3) NF-κB (9) NOD-like Receptor (NLR) (1) Oxidative Phosphorylation (1) p97 (1) Parasite (7) PARP (2) PERK (1) Phosphatase (2) PROTAC Linkers (9) PROTACs (25) RAD51 (1) Raf (1) Ras (1) Reactive Oxygen Species (2) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) Ser/Thr Protease (2) SHP2 (1) SNIPERs (5) STING (2) Target Protein Ligand-Linker Conjugates (1) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (137) Cardiovascular Disease (2) Endocrinology (1) Infection (13) Inflammation/Immunology (33) Metabolic Disease (9) Neurological Disease (12)
Click Chemistry:	PROTAC Synthesis (2) Azide (1) Alkynes (1)

187

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: Proteasome

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157032

Proteasome-IN-5

Proteasome Others

Proteasome-IN-5 (compound 5) is a proteasome inhibitor .

Proteasome-IN-5	Proteasome	Others
Proteasome-IN-5 (compound 5) is a proteasome inhibitor .

HY-134961

Z-Ala-Arg-Arg-AMC Fluorogenic proteasome Substrate; Z-ARR-AMC	Proteasome	Others
Z-Ala-Arg-Arg-AMC (Fluorogenic Proteasome Substrate) is a fluorogenic substrate for assaying trypsin-like activity of proteasome .

HY-144369

Proteasome-IN-4	Proteasome	Cancer
Proteasome-IN-4 is an excellent and non-covalent *proteasome* inhibitor (IC₅₀=8.39 nM). Proteasome-IN-4 has potent antiproliferative activities against RPMI-8226, MM-1S and MV-4-11 cell lines. Proteasome-IN-4 can be used for cancer research .

HY-150591

20S Proteasome-IN-3

Proteasome Cancer

20S Proteasome-IN-3 is a 20S proteasome β5 subunit inhibitor (IC₅₀=1.64 μM) . 20S Proteasome-IN-3 shows anti-tumor proliferation activity .
HY-157035

Proteasome β2c/i-IN-1

Proteasome Others

Proteasome β2c/i-IN-1 (compound 37) is a subunit-selective human proteasome β2c and β2i inhibitor .

*20S Proteasome-IN-3*	Proteasome	Cancer
20S Proteasome-IN-3 is a 20S proteasome β5 subunit inhibitor (IC₅₀=1.64 μM) . 20S Proteasome-IN-3 shows anti-tumor proliferation activity .

Proteasome β2c/i-IN-1	Proteasome	Others
Proteasome β2c/i-IN-1 (compound 37) is a subunit-selective human proteasome β2c and β2i inhibitor .

HY-151195

*20S Proteasome-IN-4*	Proteasome Parasite	Infection
20S Proteasome-IN-4 (Compound 7) is a brain-penetrant, parasite-selective, orally active 20S proteasome inhibitor with an IC₅₀ of 6.3 nM against T. b. brucei 20S proteasome. 20S Proteasome-IN-4 can be used for the research of human African trypanosomiasis (HAT) .

HY-150590

*20S Proteasome-IN-2*	Proteasome	Cancer
20S Proteasome-IN-2 is a human 20S proteasome inhibitor. 20S Proteasome-IN-2 shows high selectivity to its β5 subunit with the IC₅₀ of 0.18 μM. 20S Proteasome-IN-2 displays anti-proliferative effect in vitro and in vivo, and arrests cell cycle at G2/M .

HY-P3414A

Proteasome-activating peptide 1 TFA 1 Publications Verification	Proteasome	Neurological Disease
Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .

HY-100172

Proteasome-IN-1

Proteasome Cancer

Proteasome-IN-1 is a proteasome inhibitor extracted from patent WO 2013142376 A1.

Proteasome-IN-1	Proteasome	Cancer
Proteasome-IN-1 is a *proteasome* inhibitor extracted from patent WO 2013142376 A1.

HY-139331

*20S Proteasome-IN-1*	Proteasome	Neurological Disease Inflammation/Immunology Cancer
20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research .

HY-157212

*PARP-1/Proteasome-IN-1*	Apoptosis PARP Proteasome	Cancer
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. *PARP-1/Proteasome*-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis .

HY-107412

Proteasome inhibitor IX PS-IX; AM114	Proteasome	Cancer
Proteasome inhibitor IX (PS-IX; AM114) is a Chalcone derivative and a chymotrypsin-like activity of the 20S proteasome inhibitor with an IC₅₀ value of ~1 μM. Proteasome inhibitor IX exhibits HCT116 p53 ^+/+ cells growth inhibitory activity with an IC₅₀ value of 1.49 μM. Proteasome inhibitor IX has potent anticancer activity .

HY-150602

*20S Proteasome* activator 1**	Proteasome	Neurological Disease
20S Proteasome activator 1 is a potent 20S proteasome activator with EC₂₀₀ values of 0.3 μM, 0.7 μM and 1.8 μM for trypsin-like site, chymotrypsin-like site and caspase-like site. 20S Proteasome activator 1 translates well in a cellular system, preventing the accumulation of the pathogenic A53T mutant of α-synuclein. 20S Proteasome activator 1 can be used for researching neurodegenerative diseases .

HY-P10060

Boc-Val-Gly-Arg-AMC

Biochemical Assay Reagents Others

Boc-Val-Gly-Arg-AMC is a peptide substrate that can be used to study activity of the proteasome .
HY-P10003

iso-VQA-ACC

Proteasome Cancer

iso-VQA-ACC is a substrate for constitutive proteasome .
HY-P10003A

iso-VQA-ACC TFA

Proteasome Others

iso-VQA-ACC TFA is a constitutive proteasome substrate .

Boc-Val-Gly-Arg-AMC	Biochemical Assay Reagents	Others
Boc-Val-Gly-Arg-AMC is a peptide substrate that can be used to study activity of the proteasome .

iso-VQA-ACC	Proteasome	Cancer
iso-VQA-ACC is a substrate for constitutive proteasome .

iso-VQA-ACC TFA	Proteasome	Others
iso-VQA-ACC TFA is a constitutive proteasome substrate .

HY-P1258

PSI proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent *proteasome* inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-135396

(1S,2S)-Bortezomib	Proteasome Apoptosis	Cancer
(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective *proteasome* inhibitor, and potently inhibits 20S proteasome (K_i of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans .

HY-137281

HMB-Val-Ser-Leu-VE	Ser/Thr Protease	Others
HMB-Val-Ser-Leu-VE is a prototype vinyl ester inhibitor. HMB-Val-Ser-Leu-VE is against trypsin-like (T-L) proteasome activity with an IC₅₀ of 0.033 μM .

HY-149514

BC-05	Proteasome	Cancer
BC-05 is an orally active and potent inhibitor of CD13 and *proteasome. BC-05 has an IC₅₀* value of 0.13 μM for human CD13 and an IC₅₀ value of 1.39 μM for the 20S proteasome. BC-05 can be used in multiple myeloma research .

HY-153582

ML 2-23

PROTACs Bcr-Abl Cancer

ML 2-23 is a potent PROTAC BCR-ABL degrader. ML 2-23 is selectively degrade BCR-ABL in a proteasome-dependent manner in leukemia cells .

ML 2-23	PROTACs Bcr-Abl	Cancer
ML 2-23 is a potent PROTAC BCR-ABL degrader. ML 2-23 is selectively degrade BCR-ABL in a proteasome-dependent manner in leukemia cells .

HY-P2016

Ac-Nle-Pro-Nle-Asp-AMC	Proteasome	Others
Ac-Nle-Pro-Nle-Asp-AMC is a specific substrate for 26S proteasome. Ac-Nle-Pro-Nle-Asp-AMC can be used for the 26S proteasome caspase-like activity analysis .

HY-129867

Z-Leu-Leu-Leu-AMC

Z-LLL-AMC
Proteasome Others

Z-Leu-Leu-Leu-AMC is a fluorogenic substrate for measuring the chymotrypsin-like protease activity of the 20S proteasome .
HY-123053

Z-Leu-Leu-Glu-AMC

Z-LLE-AMC
Proteasome Others

Z-Leu-Leu-Glu-AMC is a substrate peptide, and can be used for determination of postacidic-like hydrolysing activity of 20S proteasome

Z-Leu-Leu-Leu-AMC Z-LLL-AMC	Proteasome	Others
Z-Leu-Leu-Leu-AMC is a fluorogenic substrate for measuring the chymotrypsin-like protease activity of the 20S proteasome .

Z-Leu-Leu-Glu-AMC Z-LLE-AMC	Proteasome	Others
Z-Leu-Leu-Glu-AMC is a substrate peptide, and can be used for determination of postacidic-like hydrolysing activity of 20S proteasome

HY-W054146

RAMB4 1 Publications Verification	Proteasome	Cancer
RAMB4 is a *ubiquitin-proteasome* system (UPS)-stressor*. RAMB4 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. RAMB4 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome* catalytic activities. Anticancer activity .

HY-137286

Z-Leu-Leu-Glu-βNA Z-Leu-Leu-Glu-β-naphthylamide	Proteasome	Others
Z-Leu-Leu-Glu-βNA (Z-Leu-Leu-Glu-β-naphthylamide) is a substrate for determination of the glutamylpeptidyl-peptide hydrolase activity of the 20S proteasome .

HY-144980

E3 ligase Ligand 21

Ligands for E3 Ligase Cancer

E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .

E3 ligase Ligand 21	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .

HY-144983

E3 ligase Ligand 22	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 22 (compound 139) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .

HY-155103

Antitrypanosomal agent 15	Proteasome Parasite	Infection
Antitrypanosomal agent 15 (compound 26) is an orally active, brain-penetrant, selective inhibitor against **Trypanosoma cruzi proteasome, with an _pIC₅₀** of 7.4 and <4 for T. cruzi and human proteasome, respectively. Antitrypanosomal agent 15 has favorable ADME properties and can be used for Chagas disease study .

HY-144985

E3 ligase Ligand 23	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 23 (compound 17-6) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .

HY-153034

LONP1-IN-2	Others	Cancer
LONP1-IN-2 (compound 9d) is a potent and selective LONP1 inhibitor with IC₅₀ values of 0.187 μM and >10 μM for LONP1 and 20S proteasome, respectively. LONP1-IN-2 can be used in research of cancer .

HY-13259D

MG-132 (negative control)

Others Cancer

MG-132 negative control is the negative control form of MG-132 (HY-13259). MG-132 is a potent proteasome and calpain inhibitor .
HY-123051

Ac-WLA-AMC

Proteasome Inflammation/Immunology

Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate .

MG-132 (negative control)	Others	Cancer
MG-132 negative control is the negative control form of MG-132 (HY-13259). MG-132 is a potent proteasome and calpain inhibitor .

Ac-WLA-AMC	Proteasome	Inflammation/Immunology
Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate .

HY-12113

Oprozomib ONX 0912; PR-047	Proteasome Autophagy Apoptosis	Cancer
Oprozomib (PR-047) is an orally bioavailable and selective peptide epoxyketone *proteasome* inhibitor with IC₅₀s of 36 and 82 nM for proteasome (β5) and immunoproteasome (LMP7), respectively. Oprozomib (ONX 0912) induces apoptosis in MM cells .

HY-13259

MG-132 Maximum Cited Publications 872 Publications Verification Z-Leu-Leu-Leu-al; MG132	Proteasome Autophagy Apoptosis	Cancer
MG-132 (Z-Leu-Leu-Leu-al) is a potent *proteasome* and calpain inhibitor with IC₅₀s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis .

HY-P4284

Z-GGF-CMK	ClpP Proteasome	Others
Z-GGF-CMK is a protease inhibitor, inhibits ClpP1P2 and proteasome. Z-GGF-CMK exhibits cytotoxic activity against HepG2 cells with a CC₅₀ value of 125 μM .

HY-160289

ARI-3144	Proteasome	Cancer
ARI-3144 is an excellent substrate for fibroblast activation protein (FAP). ARI-3144 is a FAP-activated proteasome inhibitor that can be used for the research of solid tumors .

HY-127102

GSK3494245 DDD01305143	Parasite Proteasome	Infection
GSK3494245 (DDD01305143) is a potent, orally active, and selective inhibitor of the chymotrypsin-like activity of the parasite *proteasome* binding in a site sandwiched between the β4 and β5 subunits (IC₅₀=0.16 μM for WT L. donovani proteasomes). GSK3494245 moderately inhibits chymotrypsin-like activity of human proteasome (IC₅₀: purified 26S=13 µM; enriched THP-1 extracts IC₅₀=40µM). GSK3494245 exhibits attractive biological and biosafety properties .

HY-P1258A

PSI TFA proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA	Proteasome	Infection Cancer
PSI (TFA) is a potent *proteasome* inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-10454

Delanzomib 1 Publications Verification CEP-18770	Proteasome NF-κB Apoptosis	Cancer
Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC₅₀ of 3.8 nM. Delanzomib inhibits NF-κB activity, induces cancer cell apoptotic, and has strong antiangiogenic and anti-cancer activities .

HY-N10332

Leptosphaerodione	Proteasome	Cancer
Leptosphaerodione, isolated from Remotididymella sp. Fungus, is a potent *ubiquitin-proteasome* system (UPS**) inhibitor. Leptosphaerodione exhibits cytotoxicity in HeLa cells with IC₅₀ value of 3.2 μM. Anti-tumor agent .

HY-136563

RA375	Proteasome Apoptosis Reactive Oxygen Species	Cancer
RA375 is a *RPN13 (26S proteasome* regulatory subunit)** inhibitor. RA375 activates UPR signaling, ROS production and apoptosis. RA375 exhibits ten-fold greater activity against cancer lines than RA190, reflecting its nitro ring substituents and the addition of a chloroacetamide warhead .

HY-120060

GNF6702	Parasite	Infection
GNF6702 is a selective inhibitor of the kinetoplastid proteasome. GNF6702 clears parasites in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis .

HY-120722

TCH-165 1 Publications Verification	Proteasome	Cancer
TCH-165 is a small molecule modulator of proteasome assembly, which increases 20S levels and facilitates 20S-mediated protein degradation .

HY-W017227

Alloxan hydrate	Proteasome	Metabolic Disease
Alloxan hydrate is a diabetogenic agent to induce diabetes. Alloxan hydrate is a *proteasome* inhibitor. Alloxan causes diabetes in experimental animals through its ability to destroy the insulin-secreting B-cells of the pancreas .

HY-141543

YW2065	β-catenin	Cancer
YW2065 is an Axin-1 stabilizer. Axin-1 is a scaffolding protein that regulates proteasome degradation of β-catenin. YW2065 exhibits anti-colorectal cancer effects via dual activities of wnt/β-catenin signaling inhibition and AMPK activation .

HY-19934A

Pifusertib hydrochloride TAS-117 hydrochloride	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) hydrochloride is a potent, selective, orally active allosteric Akt inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib hydrochloride triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib hydrochloride induces apoptosis and autophagy .

HY-19934

Pifusertib TAS-117	Akt Apoptosis Autophagy	Cancer
Pifusertib (TAS-117) is a potent, selective, orally active allosteric Akt inhibitor (with IC₅₀s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib induces apoptosis and autophagy .

HY-155643

PROTAC TG2 degrader-1	PROTACs Glutaminase	Cancer
PROTAC TG2 degrader-1 (compound 11) is a von Hippel-Lindau (VHL)-based PROTAC targeting tissue transglutaminase (TG2) with a K_D of 68.9 μM. PROTAC TG2 degrader-1 reduces TG2 in ovarian cancer cells in a proteasome-dependent manner .

HY-144452

Immunoproteasome inhibitor 1	Proteasome	Cancer
Immunoproteasome inhibitor 1 is a potent, reversible, time-independent immunoproteasome and *proteasome* inhibitor (K_is of 1.18, 0.27, 1.91 μM in β5c, β1i, β5i submits, respectively). Immunoproteasome inhibitor 1 can be used for the research of certain neoplastic diseases .

Cat. No.	Product Name

HY-L050

Ubiquitination Compound Library

286 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 286 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

HY-L151

PROTAC Library

230 compounds

PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy.

MCE supplies a unique collection of 230 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

HY-L012

Metabolism/Protease Compound Library

4431 compounds

Metabolism is the set of life-sustaining chemical reactions in organisms. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. Acting as catalysts, enzymes are crucial to metabolism - they allow a reaction to proceed more rapidly - and they also allow the regulation of the rate of a metabolic reaction. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. Imbalances in metabolic activities have been found to be critical in a number of pathologies, such as cardiovascular diseases, inflammation, cancer, and neurodegenerative diseases.

MCE designs a unique collection of 4431 Metabolism/Protease-related small molecules that act as a useful tool for drug discovery of metabolism-related diseases.

HY-L085

Anti-Parkinson's Disease Compound Library

1339 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1339 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L137

Molecular Glue Compound Library

35 Compounds compounds

Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention.

Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy.

MCE supplies a unique collection of 35 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

HY-L129

Target Protein Ligand Library

39 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 39 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L128

E3 Ligase Ligand Library

88 compounds

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 88 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

Cat. No.	Product Name	Target	Research Area

HY-P3414A

Proteasome-activating peptide 1 TFA 1 Publications Verification	Proteasome	Neurological Disease
Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .

HY-134961

Z-Ala-Arg-Arg-AMC Fluorogenic proteasome Substrate; Z-ARR-AMC	Proteasome	Others
Z-Ala-Arg-Arg-AMC (Fluorogenic Proteasome Substrate) is a fluorogenic substrate for assaying trypsin-like activity of proteasome .

HY-P3414

Proteasome-activating peptide 1	Peptides	Neurological Disease
Proteasome-activating peptide 1 is a peptide, which increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .

HY-P10060

Boc-Val-Gly-Arg-AMC

Biochemical Assay Reagents Others

Boc-Val-Gly-Arg-AMC is a peptide substrate that can be used to study activity of the proteasome .
HY-P10003

iso-VQA-ACC

Proteasome Cancer

iso-VQA-ACC is a substrate for constitutive proteasome .
HY-P10003A

iso-VQA-ACC TFA

Proteasome Others

iso-VQA-ACC TFA is a constitutive proteasome substrate .

HY-P1258

PSI proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent *proteasome* inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-137281

HMB-Val-Ser-Leu-VE	Ser/Thr Protease	Others
HMB-Val-Ser-Leu-VE is a prototype vinyl ester inhibitor. HMB-Val-Ser-Leu-VE is against trypsin-like (T-L) proteasome activity with an IC₅₀ of 0.033 μM .

HY-P2016

Ac-Nle-Pro-Nle-Asp-AMC	Proteasome	Others
Ac-Nle-Pro-Nle-Asp-AMC is a specific substrate for 26S proteasome. Ac-Nle-Pro-Nle-Asp-AMC can be used for the 26S proteasome caspase-like activity analysis .

HY-129867

Z-Leu-Leu-Leu-AMC

Z-LLL-AMC
Proteasome Others

Z-Leu-Leu-Leu-AMC is a fluorogenic substrate for measuring the chymotrypsin-like protease activity of the 20S proteasome .
HY-123053

Z-Leu-Leu-Glu-AMC

Z-LLE-AMC
Proteasome Others

Z-Leu-Leu-Glu-AMC is a substrate peptide, and can be used for determination of postacidic-like hydrolysing activity of 20S proteasome

HY-137286

Z-Leu-Leu-Glu-βNA Z-Leu-Leu-Glu-β-naphthylamide	Proteasome	Others
Z-Leu-Leu-Glu-βNA (Z-Leu-Leu-Glu-β-naphthylamide) is a substrate for determination of the glutamylpeptidyl-peptide hydrolase activity of the 20S proteasome .

HY-123051

Ac-WLA-AMC

Proteasome Inflammation/Immunology

Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate .

HY-P4284

Z-GGF-CMK	ClpP Proteasome	Others
Z-GGF-CMK is a protease inhibitor, inhibits ClpP1P2 and proteasome. Z-GGF-CMK exhibits cytotoxic activity against HepG2 cells with a CC₅₀ value of 125 μM .

HY-P1258A

PSI TFA proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA	Proteasome	Infection Cancer
PSI (TFA) is a potent *proteasome* inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-P1259

PR-39	Proteasome Bacterial	Inflammation/Immunology
PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric *proteasome* inhibitor. PR-39 reversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .

HY-P1259A

PR-39 TFA	Proteasome Bacterial	Inflammation/Immunology
PR-39 TFA, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric *proteasome* inhibitor. PR-39 TFAreversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 TFA stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .

HY-P4514

Z-Gly-Gly-Arg-βNA

Peptides Others

Z-Gly-Gly-Arg-βNA is the synthetic peptide substrate of trypsin-like activities of the proteasome .

HY-P5280

Ac-KQL-AMC	Ser/Thr Protease	Others
Ac-KQL-AMC is a fluorogenic substrate that can be used to quantify Trypsin-like activity, resulting in detectable fluorescence when cleaved by the proteasome .

HY-P4910

Baceridin	Proteasome Apoptosis	Cancer
Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7056

4'-Hydroxychalcone	Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Chalcones Monophenols Flavonoids Leguminosae Phenols Inflammation/Immunology Disease Research Fields Glycyrrhiza uralensis Fisch.	Oxidative Phosphorylation Proteasome
4'-Hydroxychalcone is a chalcone isolated from licorice root, with hepatoprotective activity. 4'-Hydroxychalcone inhibits TNFα-induced NF-κB activation via *proteasome* inhibition. 4'-Hydroxychalcone induces a rapid potassium release from mitochondrial vesicles and causes deterioration of respiratory control and oxidative phosphorylation of isolated rat liver mitochondria .

HY-13067

Celastrol Maximum Cited Publications 31 Publications Verification Tripterine; Tripterin	Triterpenes Structural Classification Classification of Application Fields Anti-aging Terpenoids Source classification Celastraceae Plants Tripterygium wilfordii Hook. f. Inflammation/Immunology Disease Research Fields Cancer	Proteasome Autophagy Mitophagy Apoptosis Endogenous Metabolite
Celastrol (Tripterine;Tripterin) is a *proteasome* inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC₅₀ of 2.5 μM.

HY-N10332

Leptosphaerodione	Quinones Monophenols Microorganisms Classification of Application Fields Source classification Phenols Naphthalene Quinones Disease Research Fields Cancer	Proteasome
Leptosphaerodione, isolated from Remotididymella sp. Fungus, is a potent *ubiquitin-proteasome* system (UPS**) inhibitor. Leptosphaerodione exhibits cytotoxicity in HeLa cells with IC₅₀ value of 3.2 μM. Anti-tumor agent .

HY-N11877

Antimycin A2c	Structural Classification Monophenols Marine natural products Source classification Phenols Marine microorganism	Apoptosis
Antimycin A2c (compound AE) is an antimycin alkaloid, with inhibitory pottential in HPV infected-cervical cancer. Antimycin A2c inhibits cervical cancer HeLa cells proliferation, arrests cell cycle at S phase. Antimycin A2c induces caspase dependent apoptosis, via disrupting mitochondrial function, and then activating ROS-mediated ubiquitin-dependent proteasome system, thus mediating E6/E7 oncoproteins degradation .

HY-N11620

Sadopeptins A	Structural Classification Monophenols Microorganisms Source classification Phenols	Proteasome
Sadopeptins A is a nature product that could be isolated from Streptomyces sp. Sadopeptins A is a potent proteasome inhibitor .

HY-N11621

Sadopeptins B	Structural Classification Monophenols Microorganisms Source classification Phenols	Proteasome
Sadopeptins B is a nature product that could be isolated from Streptomyces sp. Sadopeptins B is a potent proteasome inhibitor .

HY-10985

Marizomib 5+ Cited Publications Salinosporamide A; NPI-0052	Marine natural products Source classification Marine microorganism	Proteasome
Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, *pan-proteasome* inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC₅₀=3.5, 28, and 430 nM, respectively) .

HY-13821

Epoxomicin 5+ Cited Publications BU-4061T	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Inflammation/Immunology Disease Research Fields	Proteasome Apoptosis
Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible *proteasome* inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the *proteasome* and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity .

HY-N2117

Isoginkgetin 10+ Cited Publications	Structural Classification Flavonoids Ginkgoaceae Classification of Application Fields Source classification Phenols Polyphenols Plants Biflavones Ginkgo biloba Disease Research Fields Cancer	MMP Akt NF-κB Proteasome Apoptosis Autophagy
Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy .

HY-N0375

18α-Glycyrrhetinic acid	Triterpenes Classification of Application Fields Neurological Disease Leguminosae Terpenoids Source classification Plants Disease Research Fields Inflammation/Immunology Glycyrrhiza uralensis Fisch.	Proteasome NF-κB Apoptosis
18α-Glycyrrhetinic acid, a diet-derived compound, is an inhibitor of NF-kB and an activator of *proteasome, which serves as pro-longevity and anti-aggregation factor in a multicellular organism. 18α-Glycyrrhetinic acid induces apoptosis* .

HY-N0415

Trigonelline chloride 4 Publications Verification Trigonelline hydrochloride	Infection Alkaloids Structural Classification Classification of Application Fields Labiatae Source classification Pyridine Alkaloids Metabolic Disease Lactuca perennis Plants Disease Research Fields	Endogenous Metabolite Ferroptosis Apoptosis HIV Bacterial Fungal
Trigonelline chloride is an alkaloid with potential antidiabetic activity that can be isolated from Trigonella foenum-graecum L or Leonurus artemisia. Trigonelline chloride is a potent Nrf2 inhibitor that blocks Nrf2-dependent proteasome activity, thereby enhancing apoptosis in pancreatic cancer cells. Trigonelline chloride also has anti-HSV-1, antibacterial, and antifungal activity, and induces ferroptosis.

HY-N0414

Trigonelline 4 Publications Verification Trigenolline	Structural Classification Classification of Application Fields Source classification Pyridine Alkaloids Metabolic Disease Plants Endogenous metabolite Alkaloids other families Microorganisms Leguminosae Disease Research Fields Trigonella foenum-graecum Linn.	Endogenous Metabolite Ferroptosis Apoptosis HIV Bacterial Fungal
Trigonelline is an alkaloid with potential antidiabetic activity that can be isolated from Trigonella foenum-graecum L or Leonurus artemisia. Trigonelline is a potent Nrf2 inhibitor that blocks Nrf2-dependent proteasome activity, thereby enhancing apoptosis in pancreatic cancer cells. Trigonelline also has anti-HSV-1, antibacterial, and antifungal activity and induces ferroptosis.

HY-N7695

Physalin B	other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Plants Disease Research Fields Cancer	Apoptosis Autophagy
Physalin B, one of the major active steroidal constituents of Cape gooseberry, induces cell cycle arrest and triggers apoptosis in breast cancer cells through modulating p53-dependent apoptotic pathway. Physalin B inhibits the ubiquitin-proteasome pathway and induces incomplete autophagic response in human colon cancer cells in vitro .

HY-16594

Lactacystin 2 Publications Verification	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Proteasome Apoptosis ROS Kinase
Lactacystin is a potent, orally active, irreversible, cell-permeable, selective 20S *proteasome* inhibitor (IC₅₀ = 4.8 μM). Lactacystin also inhibits the lysosomal enzyme cathepsin A. Lactacystin inhibits cell growth and induces apoptosisand cell cycle arrest, and has antiviral and antioxidative activity. Lactacystin induces neurite outgrowth and hypertension. Lactacystin has the potential for the research of cancer, Neurological Disease, hypertension and Malaria, and so on ^[1] ^[2] ^[3] ^[4] ^[5] ^[6] ^[7] ^[8] ^[9] ^[10].

Species:	Human (16) Mouse (3)
Tag:	His (15) Tag Free (4) Strep (2) Avi (8)
Source:	HEK293 (8) Sf9 insect cells (1) E. coli (10)

Cat. No.	Compare	Product Name	Species	Source

HY-P701467

	PSMD7 Protein, Human (Sf9) PSMD7; 26S proteasome non-ATPase regulatory subunit 7; 26S proteasome regulatory subunit RPN8; 26S proteasome regulatory subunit S12; Mov34 protein homolog; proteasome subunit p40	Human	Sf9 insect cells
	The PSMD7 protein is a component of the 26S proteasome and promotes the ATP-dependent degradation of ubiquitinated proteins. It maintains protein homeostasis by eliminating misfolded or unnecessary proteins, thereby protecting cellular function. PSMD7 Protein, Human (Sf9) is the recombinant human-derived PSMD7 protein, expressed by Sf9 insect cells , with tag free. The total length of PSMD7 Protein, Human (Sf9) is 323 a.a., .

HY-P70213

	Gankyrin/PSMD10 Protein, Human rHu26S proteasome non-ATPase regulatory subunit 10/PSMD10; 26S proteasome Non-ATPase Regulatory Subunit 10; 26S proteasome Regulatory Subunit p28; Gankyrin; p28(GANK); PSMD10	Human	E. coli
	Gankyrin/PSMD10 protein is a critical chaperone in 26S proteasome assembly, contributing to PA700/19S regulatory complex (RC) formation. In base subcomplex assembly, it engages with PSMD10, PSMC4, PSMC5, and PAAF1, likely connecting with PSMD5, PSMC2, PSMC1, and PSMD2. Independently, Gankyrin regulates EGF-induced AKT activation by inhibiting the RHOA/ROCK/PTEN pathway. It plays a key role in RAS-induced tumorigenesis, acting as a proto-oncoprotein by negatively regulating RB1 and p53/TP53. Gankyrin overexpression leads to RB1 phosphorylation and degradation, while also competing with CDKN2A for CDK4 binding. Additionally, Gankyrin facilitates MDM2-p53/TP53 binding and promotes p53/TP53 ubiquitination by MDM2, influencing the TP53:MDM2 complex's targeting to the 26S proteasome. Involved in p53-independent apoptosis, Gankyrin regulates NF-kappa-B by retaining RELA in the cytoplasm and facilitating its XPO1/CRM1-mediated nuclear export. Gankyrin/PSMD10 Protein, Human is the recombinant human-derived Gankyrin/PSMD10 protein, expressed by E. coli, with tag free. The total length of Gankyrin/PSMD10 Protein, Human is 226 a.a., with molecular weight of ~26.0 kDa.

HY-P75989

	PSMB6 Protein, Mouse (His) proteasome subunit beta type-6; Psmb6; Lmp19	Mouse	E. coli
	PSMB6 protein is a component of the 20S core proteasome complex and participates in ubiquitin-dependent protein degradation within the 26S proteasome. This complex maintains protein homeostasis by eliminating misfolded or unnecessary proteins. PSMB6 Protein, Mouse (His) is the recombinant mouse-derived PSMB6 protein, expressed by E. coli , with N-His labeled tag. The total length of PSMB6 Protein, Mouse (His) is 205 a.a., with molecular weight of ~24.2 kDa.

HY-P701388

	PSMG3 Protein, Human PSMG3; proteasome assembly chaperone 3; PAC-3; hPAC3	Human	E. coli
	The PSMG3 protein acts as a chaperone and actively promotes the assembly of the 20S proteasome. It involves potential cooperation with the PSMG1-PSMG2 heterodimer to ensure precise assembly of the proteasome. PSMG3 Protein, Human is the recombinant human-derived PSMG3 protein, expressed by E. coli , with tag free. The total length of PSMG3 Protein, Human is 122 a.a., .

HY-P701390

	PSMG4 Protein, Human PSMG4; proteasome assembly chaperone 4; PAC-4; hPAC4	Human	E. coli
	PSMG4 protein functions as a chaperone, facilitating the assembly of the 20S proteasome. In its role as a chaperone, PSMG4 interacts with PSMG3, forming a functional complex that contributes to the proper assembly of the 20S proteasome. Notably, PSMG4 associates specifically with the alpha subunits of the 20S proteasome, highlighting its involvement in the intricate process of proteasomal maturation and functionality. PSMG4 Protein, Human is the recombinant human-derived PSMG4 protein, expressed by E. coli , with tag free. The total length of PSMG4 Protein, Human is 123 a.a., .

HY-P701389

	PSMG3 Protein, Human (His, Strep) PSMG3; proteasome assembly chaperone 3; PAC-3; hPAC3	Human	E. coli
	The PSMG3 protein acts as a chaperone and actively promotes the assembly of the 20S proteasome. It involves potential cooperation with the PSMG1-PSMG2 heterodimer to ensure precise assembly of the proteasome. PSMG3 Protein, Human (His, Strep) is the recombinant human-derived PSMG3 protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of PSMG3 Protein, Human (His, Strep) is 122 a.a., .

HY-P701391

	PSMG4 Protein, Human (His, Strep) PSMG4; proteasome assembly chaperone 4; PAC-4; hPAC4	Human	E. coli
	PSMG4 protein functions as a chaperone, facilitating the assembly of the 20S proteasome. In its role as a chaperone, PSMG4 interacts with PSMG3, forming a functional complex that contributes to the proper assembly of the 20S proteasome. Notably, PSMG4 associates specifically with the alpha subunits of the 20S proteasome, highlighting its involvement in the intricate process of proteasomal maturation and functionality. PSMG4 Protein, Human (His, Strep) is the recombinant human-derived PSMG4 protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of PSMG4 Protein, Human (His, Strep) is 123 a.a., .

HY-P76554

	PSME3 Protein, Human (His) proteasome activator complex subunit 3; REG-gamma; PA28g; PSME3	Human	E. coli
	PSME3 is a subunit of the 11S REG-gamma proteasome modulator that forms a homoheptamer and is essential for activating the trypsin-like subunit of the proteasome and inhibiting the chymotrypsin-like and PGPH subunits. PSME3 promotes MDM2-p53 interaction, leading to p53 degradation and inhibiting apoptosis after DNA damage. PSME3 Protein, Human (His) is the recombinant human-derived PSME3 protein, expressed by E. coli , with N-His labeled tag. The total length of PSME3 Protein, Human (His) is 254 a.a., with molecular weight of 28-33 kDa.

HY-P75988

	PSMA3 Protein, Human (His) proteasome subunit alpha type-3; Macropain subunit C8; PSMA3; HC8; PSC8	Human	E. coli
	PSMA3 is a protein involved in protein degradation. PSMA3 Protein, Human (His) is the recombinant human-derived PSMA3 protein, expressed by E. coli , with N-His labeled tag. The total length of PSMA3 Protein, Human (His) is 255 a.a., with molecular weight of ~30 kDa.

HY-P75990

	PSME1 Protein, Human (His) proteasome activator complex subunit 1; REG-alpha; IGUP I-5111; PA28a; IFI5111	Human	E. coli
	The PSME1 protein is critical for immunoproteasome assembly and is essential for efficient antigen processing. As part of the PA28 activator complex, PSME1, together with PSME2, actively enhances the production of class I binding peptides by altering the cleavage pattern of the proteasome. PSME1 Protein, Human (His) is the recombinant human-derived PSME1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of PSME1 Protein, Human (His) is 248 a.a., with molecular weight of ~29 kDa.

HY-P75991

	PSME2 Protein, Human (His) proteasome activator complex subunit 2; REG-beta; PA28beta; PA28b; PSME2	Human	E. coli
	PSME2 Protein, vital for immunoproteasome assembly, is crucial for efficient antigen processing. In collaboration with PSME1, the PA28 activator complex modifies the proteasome's cleavage pattern, actively contributing to class I binding peptide generation. The hexameric ring structure of this heterodimeric complex underscores its significance in orchestrating processes essential for immune responses and antigen presentation. PSME2 Protein, Human (His) is the recombinant human-derived PSME2 protein, expressed by E. coli , with N-His labeled tag. The total length of PSME2 Protein, Human (His) is 239 a.a., with molecular weight of ~29 kDa.

HY-P77766

	*HLA-A0201 LMP2 Complex Protein, Human (HEK293, His-Avi)** MHC; RMF; LMP2; LMP-2; Macropain chain 7; proteasome chain 7; PSMB9; RING12	Human	HEK293
	HLA-A0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A0201 WT-1 Complex Tetramer is recognized within the MHC class I family. HLA-A0201 LMP2 Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing human-derived HLA-A0201 LMP2 Complex protein, expressed by HEK293 , with C-Avi, C-His labeled tag. HLA-A*0201 LMP2 Complex Protein, Human (HEK293, His-Avi), has molecular weight of 52-56 kDa.

HY-P77767

	*HLA-A0201 LMP2 Complex Protein, Human (Biotinylated, HEK293, His-Avi)** MHC; RMF; LMP2; LMP-2; Macropain chain 7; proteasome chain 7; PSMB9; RING12	Human	HEK293
	HLA-A0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A0201 WT-1 Complex Tetramer is recognized within the MHC class I family. HLA-A0201 LMP2 Complex Protein, Human (Biotinylated, HEK293, His-Avi) is a recombinant protein dimer complex containing human-derived HLA-A0201 LMP2 Complex protein, expressed by HEK293 , with C-Avi, C-His labeled tag. HLA-A*0201 LMP2 Complex Protein, Human (Biotinylated, HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P77768

	*HLA-A0201 LMP2 Complex Tetramer Protein, Human (HEK293, His-Avi)** MHC; RMF; LMP2; LMP-2; Macropain chain 7; proteasome chain 7; PSMB9; RING12	Human	HEK293
	HLA-A0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A0201 WT-1 Complex Tetramer is recognized within the MHC class I family. HLA-A0201 LMP2 Complex Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing human-derived HLA-A0201 LMP2 Complex Tetramer protein, expressed by HEK293 , with C-Avi, C-His labeled tag. HLA-A*0201 LMP2 Complex Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P77771

	*Chimeric HLA-A0201 LMP2 Protein, Human&Mouse (HEK293, His-Avi)** MHC; RMF; LMP2; LMP-2; Macropain chain 7; proteasome chain 7; PSMB9; RING12	Mouse	HEK293
	HLA-A0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A0201 WT-1 Complex Tetramer is recognized within the MHC class I family. Chimeric HLA-A0201 LMP2 Protein, Human&Mouse (HEK293, His-Avi) is the recombinant mouse-derived Chimeric HLA-A0201 LMP2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. Chimeric HLA-A*0201 LMP2 Protein, Human&Mouse (HEK293, His-Avi), has molecular weight of 52-65 kDa.

HY-P700933

	*HLA-A1101 LMP2 Complex Protein, Human (SSCSSCPLTK, HEK293, His-Avi)** MHC; RMF; LMP2; LMP-2; Macropain chain 7; proteasome chain 7; PSMB9; RING12	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 LMP2 Complex Protein, Human (SSCSSCPLTK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and SSCSSCPLTK peptide. HLA-A*1101 LMP2 Complex Protein, Human (SSCSSCPLTK, HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P77772

	*Chimeric HLA-A0201 LMP2 Tetramer Protein, Human&Mouse (HEK293, His-Avi)** MHC; RMF; LMP2; LMP-2; Macropain chain 7; proteasome chain 7; PSMB9; RING12	Mouse	HEK293
	HLA-A0201 MAGE-A4 Complex Protein, a member of the major histocompatibility complex (MHC) class I family, is highlighted. Additionally, the Chimeric HLA-A0201 WT-1 Complex Tetramer is recognized within the MHC class I family. Chimeric HLA-A0201 LMP2 Tetramer Protein, Human&Mouse (HEK293, His-Avi) is the recombinant mouse-derived Chimeric HLA-A0201 LMP2 Tetramer protein, expressed by HEK293 , with C-Avi, C-His labeled tag. Chimeric HLA-A*0201 LMP2 Tetramer Protein, Human&Mouse (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P700932

	*HLA-A1101 LMP2 Complex Protein, Human (Biotinylated, SSCSSCPLTK, HEK293, His-Avi)** MHC; RMF; LMP2; LMP-2; Macropain chain 7; proteasome chain 7; PSMB9; RING12	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 LMP2 Complex Protein, Human (Biotinylated, SSCSSCPLTK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and SSCSSCPLTK peptide. HLA-A*1101 LMP2 Complex Protein, Human (Biotinylated, SSCSSCPLTK, HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P700934

	*HLA-A1101 LMP2 Complex Tetramer Protein, Human (SSCSSCPLTK, HEK293, His-Avi)** MHC; RMF; LMP2; LMP-2; Macropain chain 7; proteasome chain 7; PSMB9; RING12	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 LMP2 Complex Tetramer Protein, Human (SSCSSCPLTK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and SSCSSCPLTK peptide. HLA-A*1101 LMP2 Complex Tetramer Protein, Human (SSCSSCPLTK, HEK293, His-Avi), has molecular weight of 260-265 kDa.

Cat. No.	Product Name	Chemical Structure

HY-10227S

Bortezomib-d8
Bortezomib-d₈ is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].

HY-10455S

Carfilzomib-d8

Carfilzomib-d₈ is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.

Cat. No.	Product Name	Application	Reactivity

HY-P80437

Proteasome 20S LMP7 Antibody	WB, ICC, IF, IHC-P, FC	Human, Mouse, Rat
Proteasome 20S LMP7 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 30 kDa, targeting to Proteasome 20S LMP7. It can be used for WB,ICC,IF,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P82004

Proteasome alpha 6 Antibody (YA1749)

proteasome subunit alpha 6; IOTA; p27K; PROS27
WB, ICC/IF Human, Mouse, Rat
HY-P81999

Proteasome alpha 2 Antibody (YA1744)

HC3; PMSA2; proteasome component C3; PSC2; PSC3; psmA2
WB, IHC-F, IHC-P, ICC/IF Human, Mouse, Rat

HY-P80876

Proteasome beta 8 Antibody (YA684) PSMB8; LMP7; PSMB5i; RING10; Y2; proteasome subunit beta type-8; Low molecular mass protein 7; Macropain subunit C13; Multicatalytic endopeptidase complex subunit C13; proteasome component C13; proteasome subunit beta-5i; Really interesting	WB, IHC-F, IHC-P, ICC/IF	Human, Rat
Proteasome beta 8 Antibody (YA684) is a non-conjugated and Mouse origined monoclonal antibody about 30 kDa, targeting to Proteasome beta 8 (3G3). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Rat.

HY-P82641

PSMA3 Antibody (YA2386) PSMA3; HC8; PSC8; proteasome subunit alpha type-3; Macropain subunit C8; Multicatalytic endopeptidase complex subunit C8; proteasome component C8	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat

HY-P82020

PSMA4 Antibody (YA1765)

proteasome subunit alpha 4; HC9; PSC9; HsT17706
WB, IHC-F, IHC-P, ICC/IF, IP Human, Mouse, Rat
HY-P82556

PSMA1 Antibody (YA2301)

NU; HC2; PROS30; psmA1; PSC2; proteasome 20S C2
WB, IHC-P, ICC/IF, IP, FC Human, Mouse, Rat
HY-P82639

PSMA2 Antibody (YA2384)

HC3; PMSA2; proteasome component C3; PSC2; PSC3; psmA2
WB, IHC-P, ICC/IF, FC Human, Mouse, Rat
HY-P82505

PSMD14 Antibody (YA2250)

26S proteasome non-ATPase regulatory subunit 14; PAD1; POH1; Psmd14; RPN11
WB, IHC-P, ICC/IF Human, Mouse, Rat
HY-P82002

Proteasome beta 9 Antibody (YA1747)

Beta1i; LMP2; PSMB 9; PSMB6i; PSMB9; RING12
WB, ICC/IF Human, Mouse, Rat

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks